The AML Global Portal were delighted to speak to Adrian Ochsenbein, University of Bern, Bern, CH, during the European School of Hematology (ESH) Translational Research Conference on AML. We asked Adrian Ochsenbein: Why should we target CD70 in leukemias? He describes the results of a dose escalation study targeting CD70 to reduce proliferation in AML and concludes by discussing early phase II data.
ESH 2019 | Why should we target CD70 in leukemias?
Was this article informative? Thank you for your feedback!100% of people found this article informative